single stranded DNA binding protein 3Genealiases: CSDP · SSDP · SSDP1
Q-omics provides the consensus-scored SSBP3 profile across patient tissues and cancer cell-line models. SSBP3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SSBP3 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, SSBP3 RNA expression shows 18,405 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, and KIRP as cancer lineages where SSBP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SSBP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SSBP3 survival associations across molecular data types. SSBP3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SSBP3 RNA expression–survival associations across cancer types. High SSBP3 expression shows favorable associations in UVM, CESC, HNSC, KIRC, MESO and PCPG. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for SSBP3 RNA expression.
This table summarizes SSBP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SSBP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SSBP3 shows lower tumor expression in KIRP, KICH, THCA, BLCA and BRCA and higher tumor expression in HNSC. The KIRP box plot shows higher SSBP3 RNA expression in normal versus tumor tissue (log2 FC = −1.219, t-test p < 0.001).
This table shows molecular features associated with SSBP3 in patient tissues and cancer cell lines. In patient samples, SSBP3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SSBP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Leukemia.
